ArticleJournal of the American Chemical Society2025
Chemical Engineering of Transcription Factors Uncovered Cell-Permeable μMax Modulators.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Conformational reprogramming of c-MycRSC chemical biology · 2026Article
- Chemical Synthesis of Mirror-Image Proteins Reveals Chirality-Dependent Cellular Uptake Mediated by a Cell-Penetrating Peptide.Journal of the American Chemical Society · 2026Article
- Advancing protein engineering via organic chemistry.Communications chemistry · 2026Review
- Engineering Light-Responsive Transcription Factors via Strategic Masking of Post-translational Modification Residues.Bioconjugate chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcription factor engineering has emerged as a powerful strategy for generating novel proteins for fundamental research and biomedical applications. Although various analogs have been developed, they remain largely constrained to native sequences and structures. The generation of advanced analogs bearing noncanonical modifications with enhanced functional properties remains limited. Here we combined rational design with total synthesis to engineer novel abiotic transcription factors with enhanced stability and cell permeability. Using solid-phase synthesis and native chemical ligation, we created a library of 30 Max-derived transcription factor analogs incorporating novel modifications, such as sequence mutations and aromatic staples at strategic sites. Through DNA-binding analysis and cellular uptake studies, we identified the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.